We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) closed the most recent trading day at $45.60, moving +2.86% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.44%. Elsewhere, the Dow saw a downswing of 0.09%, while the tech-heavy Nasdaq depreciated by 2.22%.
The stock of medical device manufacturer has fallen by 23.28% in the past month, lagging the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. In that report, analysts expect Boston Scientific to post earnings of $0.83 per share. This would mark year-over-year growth of 10.67%. Simultaneously, our latest consensus estimate expects the revenue to be $5.39 billion, showing a 6.54% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $21.61 billion, signifying shifts of +9.8% and +7.65%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.51% downward. Boston Scientific is currently sporting a Zacks Rank of #4 (Sell).
Looking at valuation, Boston Scientific is presently trading at a Forward P/E ratio of 13.2. This valuation marks a discount compared to its industry average Forward P/E of 17.43.
One should further note that BSX currently holds a PEG ratio of 0.85. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. BSX's industry had an average PEG ratio of 1.52 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 167, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
Boston Scientific (BSX - Free Report) closed the most recent trading day at $45.60, moving +2.86% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.44%. Elsewhere, the Dow saw a downswing of 0.09%, while the tech-heavy Nasdaq depreciated by 2.22%.
The stock of medical device manufacturer has fallen by 23.28% in the past month, lagging the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. In that report, analysts expect Boston Scientific to post earnings of $0.83 per share. This would mark year-over-year growth of 10.67%. Simultaneously, our latest consensus estimate expects the revenue to be $5.39 billion, showing a 6.54% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $21.61 billion, signifying shifts of +9.8% and +7.65%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.51% downward. Boston Scientific is currently sporting a Zacks Rank of #4 (Sell).
Looking at valuation, Boston Scientific is presently trading at a Forward P/E ratio of 13.2. This valuation marks a discount compared to its industry average Forward P/E of 17.43.
One should further note that BSX currently holds a PEG ratio of 0.85. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. BSX's industry had an average PEG ratio of 1.52 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 167, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.